Fevipiprant (QAW039) is a selective DP2 antagonist initially developed for asthma. Preclinical work suggests potential to counter PGD2‑driven follicle miniaturisation.
Fevipiprant
QAW039
Fevipiprant (QAW039) is a selective DP2 antagonist initially developed for asthma. Preclinical work suggests potential to counter PGD2‑driven follicle miniaturisation.
{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://longevityone.org/entity/fevipiprant/",
"url": "https://longevityone.org/entity/fevipiprant/",
"name": "Fevipiprant"
}
LongevityOne is a global platform dedicated to curing human aging. We consolidate advanced research, emerging technology, and unified data to accelerate innovation in the longevity space. Our mission is to serve scientists, bio-hackers, and advocates with trustworthy resources and collaborative tools.
LongevityOne was founded by Michael Peres, a serial entrepreneur and biomedical researcher with a background in Mathematics, Computer Science, and Jewish Studies. He is currently pursuing Biomedical Engineering to strengthen the technical foundation of LongevityOne’s work. Learn more about him at michaelperes.com.
We don’t just report on breakthroughs — we unify them. LongevityOne acts as a central repository where research, news, tools, and contributors converge. By removing silos in the aging research ecosystem, we accelerate progress toward reversing age-related decline.
Our platform is built for:
Researchers in biotechnology, genetics, and aging
Medical professionals and institutions
Bio-hackers and health optimizers
Investors in life-extension technologies
Public advocates for healthy aging
Our core objective is to contribute to the development of a foundational cure for aging. We aim to reshape the human experience of aging by supporting breakthrough research, increasing public understanding, and fostering international collaboration over the next 15 years.
Whether you’re a researcher, journalist, developer, or longevity enthusiast, we welcome your participation. Email us at [email protected] to explore partnerships, media opportunities, or to join our contributor network.